Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

46.460
-1.740-3.61%
Volume:12.04M
Turnover:568.78M
Market Cap:308.36B
PE:33.77
High:49.000
Open:48.300
Low:46.040
Close:48.200
52wk High:94.869
52wk Low:46.040
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.19
T/O Rate:4.67%
Dividend:0.23
Dividend Rate:0.50%
EPS(LYR):1.376
ROE:12.46%
ROA:7.02%
PB:4.10
PE(LYR):33.77
PS:8.44

Loading ...

Movement Alert|Hengrui Medicine Rises 3.28% in Regular Trading, ASCO Showcase and Buyback Resumption Boost Sentiment

Market Focus
·
Jun 05

Hengrui Pharma Buys Back 420,000 A Shares for RMB 19.82 Million

Bulletin Express
·
Jun 04

Hengrui Pharma Conducts Share Buyback on June 4th

Stock News
·
Jun 04

AH Premium and Deviation Rankings for June 4th

Stock News
·
Jun 04

Movement Alert|Hengrui Medicine Falls 3.11% in Regular Trading, Policy Headwinds Continue to Pressure Innovative Drug Stocks

Market Focus
·
Jun 04

Major Tech and Pharma Stocks Decline in Hong Kong Market

Deep News
·
Jun 03

Stock Track | Hengrui Pharma Plummets 5.01% Intraday on Dual Policy Headwinds from US COINS Act and China Export Controls

Stock Track
·
Jun 03

Movement Alert|Hengrui Medicine Falls 3.4% in Regular Trading, Dual Policy Headwinds from US COINS Act and China Export Controls Continue to Pressure Innovative Pharma

Market Focus
·
Jun 03

Hengrui Pharma Reports Cumulative Share Buyback of 12.06 Million A-Shares by End of May

Stock News
·
Jun 02

Hengrui Pharma Reports No Share Capital Changes for May 2026; H-Share Public Float Stands at 3.89%

Bulletin Express
·
Jun 02

AH Share Premium and Deviation Data as of June 2nd

Stock News
·
Jun 02

AH Share Premium and Deviation Rankings as of June 1st

Stock News
·
Jun 01

HENGRUI PHARMA Reports 2025 Revenue of 31.63 Billion Yuan, Up 13.02% Year-on-Year

Deep News
·
May 29

AH Share Premium and Deviation Rankings as of May 29 Close

Stock News
·
May 29

Movement Alert|Hengrui Medicine Rises 3.01% in Regular Trading, Class 1 Innovative Drug Luzunore Sodium Tablets Approved for Market

Market Focus
·
May 29

HENGRUI PHARMA's Novel Drug SHR4640 Tablets Receive Marketing Authorization

Stock News
·
May 28

Jiangsu Hengrui Pharmaceuticals - Received Nmpa Notice Approving Class 1 Innovative Drug Ruzinurad Tablets (Shr4640 Tablets) for Marketing

THOMSON REUTERS
·
May 28

HENGRUI PHARMA's Subsidiary Receives Clinical Trial Approval for SHR-1819 Injection

Stock News
·
May 28

Movement Alert|Hengrui Medicine Falls 3.08% in Regular Trading, COINS Act Biotech Expansion Threat Continues to Pressure Stock

Market Focus
·
May 28

AH Premium and Deviation Rankings as of May 27th

Stock News
·
May 27